Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HINT1 | P49773 | 5/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19941645 | 0.93 | RXFP1 (0.59) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL19941646 | 0.93 | RXFP1 (0.59) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL19922931 | 0.93 | RXFP1 (0.59) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL19938134 | 0.93 | RXFP1 (0.59) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL19938137 | 0.93 | RXFP1 (0.59) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL2675838 | 0.91 | RXFP1 (0.67) | RXFP1HINT1APOBEC3GHPGDNT5E | |
| SCHEMBL19941619 | 0.86 | HINT1 (0.76) | RXFP1HINT1APOBEC3GHPGDPNP | |
| SCHEMBL19938153 | 0.86 | HINT1 (0.76) | RXFP1HINT1APOBEC3GHPGDPNP | |
| SCHEMBL19941620 | 0.86 | HINT1 (0.76) | RXFP1HINT1APOBEC3GHPGDPNP | |
| SCHEMBL19922943 | 0.86 | PI4KA (0.64) | HINT1HPGDNT5EPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173797-B2 | Sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173797-B2 | Sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173797-B2 | Sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2006130161-A2 | THERAPEUTIC COMPOUNDS DERIVED FROM SPIDER VENOM AND THEIR METHOD OF USE | THE CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | RXFP1 3050/4885HINT1 920/4885APOBEC3G 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.